CVM Cel-Sci Corporation
$1.59▼ -3.05%
Healthcare
Other
Volume 106.7K
Avg Volume (10D) 146.8K
Key Metrics & Fundamentals
Market Cap
$27.97M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.89 - 9.35
% vs 50 MA
-6.79%
% vs 200 MA
-38.61%
RSI-14
43.0
MACD Histogram
-0.0500
Beta (1Y vs SPY)
1.58
Free Cash Flow
-$4.03M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.61M
COGS
–
Operating Exp
$5.56M
Operating Income
-$5.56M
EBIT
-$5.56M
Pretax Income
-$5.67M
Net Income
-$5.67M
EPS (Diluted)
-0.47
Price & Volume History
Loading chart…
Recent News
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
Business Wire · Oct 26, 2026 8:00 AM ET
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
Business Wire · Sep 15, 2026 8:37 AM ET
CEL-SCI Reports Fiscal Third Quarter 2026 Results
Business Wire · Aug 17, 2026 8:30 AM ET
Cel-Sci: Fiscal Q3 Earnings Snapshot
Associated Press · Aug 14, 2026 5:16 PM ET
CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study
Business Wire · Aug 4, 2026 8:00 AM ET
Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
Business Wire · Jul 30, 2026 8:31 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CVM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.